Engineered EVs ‐Mediated miR ‐222 Targeting PTEN / FN1 Axis Reverses Anthracycline Resistance in HER2 ‐Negative Breast Cancer
Cancer Science · 2025
DOI: 10.1111/cas.70118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Sujin Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: MicroRNAs, Breast Neoplasms, Drug Resistance, Neoplasm, PTEN Phosphohydrolase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Changzhou High-Level Medical Talents Training Project, China Postdoctoral Science Foundation, Changzhou Science and Technology Program.
Abstract (Originalsprache)
Anthracycline resistance represents a critical therapeutic challenge in breast cancer treatment, wherein alterations in the tumor immune microenvironment and enhanced cellular resistance mechanisms facilitate chemoresistance progression. Transcriptome analysis of 142 HER2‐negative breast cancer patients undergoing anthracycline‐based chemotherapy revealed four distinct tumor‐infiltrating cell subtypes, with subtype D exhibiting elevated M1 macrophage infiltration and superior prognostic outcomes. Differential expression analysis identified miR‐222 as the predominantly upregulated microRNA in adriamycin‐resistant cells, while Tandem Mass Tag mass spectrometry‐based quantitative analysis elucidated PTEN as its direct target and FN1 as a crucial downstream mediator. Engineered extracellular vesicles (EVs) carrying a miR‐222 inhibitor were developed to reverse adriamycin resistance via PTEN/FN1 signaling modulation. Molecular docking analysis found specific PTEN‐FN1 protein interactions characterized by stable hydrogen bonds at ARG142‐ASP23 and ARG15‐GLU95. In xenograft models, EVs‐mediated delivery of the miR‐222 inhibitor significantly attenuated MCF‐7/ADR tumor progression through miR‐222 suppression and PTEN restoration, with concordant molecular alterations observed in serum‐derived EVs. Our findings establish a novel mechanism of EVs‐mediated drug resistance through the microRNA‐222/PTEN/FN1 axis and present Engineered EVs as a promising therapeutic strategy for anthracycline resistance in breast cancer, while highlighting circulating EVs profiles as potential treatment monitoring biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
- Post-Doctoral Working Station, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
- Department of Breast Surgery, Changzhou No. 2 People's Hospital, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, China.
- Center of Clinical Laboratory, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Nanjing, China.
- Department of Traditional Chinese Medicine, Xuanwu District Hospital of Traditional Chinese Medicine, Nanjing, China.
- Department of Breast Surgery, Changzhou Cancer Hospital, Changzhou, China.
ORCID-Profile: Sujin Yang, Weixian Chen
Förderung
- Changzhou High-Level Medical Talents Training Project
- China Postdoctoral Science Foundation
- Changzhou Science and Technology Program
- Excellent Post-doctoral Program of Jiangsu Province
- National Natural Science Foundation of China
- High-level Innovative and Entrepreneurial Talent Introduction Plan of Jiangsu Province
Zitieren
APA
Yang, S., Yang, M., Shao, Q., Wang, D., Zhong, S., Yang, S., Gao, H., Qin, X., & Chen, W. (2025). Engineered EVs ‐Mediated miR ‐222 Targeting PTEN / FN1 Axis Reverses Anthracycline Resistance in HER2 ‐Negative Breast Cancer. Cancer Science. https://doi.org/10.1111/cas.70118
Vancouver
Yang S, Yang M, Shao Q, Wang D, Zhong S, Yang S, et al. Engineered EVs ‐Mediated miR ‐222 Targeting PTEN / FN1 Axis Reverses Anthracycline Resistance in HER2 ‐Negative Breast Cancer. Cancer Science. 2025. doi:10.1111/cas.70118
BibTeX
@article{Yang2025,
author = {Yang, Sujin and Yang, Mei and Shao, Quanfeng and Wang, Dandan and Zhong, Shanliang and Yang, Suyu and Gao, Haiyan and Qin, Xihu and Chen, Weixian},
title = {Engineered EVs ‐Mediated miR ‐222 Targeting PTEN / FN1 Axis Reverses Anthracycline Resistance in HER2 ‐Negative Breast Cancer},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70118}
}
EUVIMED